Nail Psoriasis and Quality-of-Life Measurement in Clinical Trials: Call for the Use of Nail-Specific Instruments

被引:6
作者
Blome, Christine [1 ]
Augustin, Matthias [1 ]
Klein, Toni Maria [1 ]
机构
[1] Univ Med Ctr Hamburg Eppendorf UKE, Inst Hlth Serv Res Dermatol & Nursing IVDP, Martinistr 52, D-20246 Hamburg, Germany
关键词
SEVERITY INDEX; ADALIMUMAB; VALIDATION; ARTHRITIS; EFFICACY; THERAPY; BURDEN; DLQI; TOOL;
D O I
10.1007/s40257-021-00622-7
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Nail involvement is frequent in people with psoriasis. It can considerably impair health-related quality of life (HRQoL) beyond the impairments due to other psoriasis symptoms, for example, because patients feel ashamed of visible nail defects or because of the functional impairment in manual activities and walking. In clinical trials on nail psoriasis, it is therefore crucial to assess whether the treatment reduces HRQoL impairments that are specific to nail psoriasis. For this purpose, two validated patient questionnaires are available, the Nail Psoriasis Quality of Life Scale (NPQ10) and the Nail Assessment in Psoriasis and Psoriatic Arthritis-Quality of Life (NAPPA-QOL). The ten-item NPQ10 has the advantage of being short and thus quick to administer. The 20-item NAPPA-QOL, in contrast, assesses the different dimensions of HRQoL which is considered a multi-dimensional construct. Yet most randomized controlled trials on nail psoriasis do not evaluate HRQoL improvement. If they do, a number of different instruments are used, most of which are not nail specific. This makes comparison of trial outcomes difficult. Harmonizing the measurement of HRQoL in future clinical trials on nail psoriasis would improve comparability across studies and would also enhance the reliability of meta-analyses.
引用
收藏
页码:747 / 755
页数:9
相关论文
共 34 条
[1]   A systematic review of the use of quality-of-life instruments in randomized controlled trials for psoriasis [J].
Ali, F. M. ;
Cueva, A. C. ;
Vyas, J. ;
Atwan, A. A. ;
Salek, M. S. ;
Finlay, A. Y. ;
Piguet, V. .
BRITISH JOURNAL OF DERMATOLOGY, 2017, 176 (03) :577-593
[2]   Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): development and validation of a tool for assessment of nail psoriasis outcomes [J].
Augustin, M. ;
Blome, C. ;
Costanzo, A. ;
Dauden, E. ;
Ferrandiz, C. ;
Girolomoni, G. ;
Gniadecki, R. ;
Iversen, L. ;
Menter, A. ;
Michaelis-Wittern, K. ;
Morita, A. ;
Nakagawa, H. ;
Reich, K. .
BRITISH JOURNAL OF DERMATOLOGY, 2014, 170 (03) :591-598
[3]   Methods of Outcomes Measurement in Nail Psoriasis [J].
Augustin, M. ;
Ogilvie, A. .
DERMATOLOGY, 2010, 221 :23-28
[4]   Nail psoriasis in Germany: epidemiology and burden of disease [J].
Augustin, M. ;
Reich, K. ;
Blome, C. ;
Schaefer, I. ;
Laass, A. ;
Radtke, M. A. .
BRITISH JOURNAL OF DERMATOLOGY, 2010, 163 (03) :580-585
[5]   Nail Psoriasis: An Updated Review and Expert Opinion on Available Treatments, Including Biologics [J].
Bardazzi, Federico ;
Starace, Michela ;
Bruni, Francesca ;
Magnano, Michela ;
Piraccini, Bianca Maria ;
Alessandrini, Aurora .
ACTA DERMATO-VENEREOLOGICA, 2019, 99 (06) :516-523
[6]   Patient-relevant needs and treatment goals in nail psoriasis [J].
Blome, C. ;
Costanzo, A. ;
Dauden, E. ;
Ferrandiz, C. ;
Girolomoni, G. ;
Gniadecki, R. ;
Iversen, L. ;
Menter, A. ;
Michaelis-Wittern, K. ;
Morita, A. ;
Nakagawa, H. ;
Reich, K. ;
Augustin, M. .
QUALITY OF LIFE RESEARCH, 2016, 25 (05) :1179-1188
[7]   Reporting of outcomes in randomized controlled trials on nail psoriasis: a systematic review [J].
Busard, C. I. ;
Nolte, J. Y. C. ;
Pasch, M. C. ;
Spuls, P. I. .
BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (03) :640-649
[8]   Identifying a Core Domain Set to Assess Psoriasis in Clinical Trials [J].
Duffin, Kristina Callis ;
Merola, Joseph F. ;
Christensen, Robin ;
Latella, John ;
Garg, Amit ;
Gottlieb, Alice B. ;
Armstrong, April W. .
JAMA DERMATOLOGY, 2018, 154 (10) :1137-1144
[9]   Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort [J].
Egeberg, Alexander ;
See, Kyoungah ;
Garrelts, Alyssa ;
Burge, Russel .
BMC DERMATOLOGY, 2020, 20 (01)
[10]   Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trial [J].
Elewski, B. E. ;
Baker, C. S. ;
Crowley, J. J. ;
Poulin, Y. ;
Okun, M. M. ;
Calimlim, B. ;
Geng, Z. ;
Servin, O. Reyes ;
Rich, P. A. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 (11) :2168-2178